表达宿主
Baculovirus-Insect Cells
纯度
≥ 90 % as determined by SDS-PAGE;≥ 90 % as determined by HPLC.
内毒素
< 1 EU/μg of the protein by LAL method.
制剂
Supplied as a 0.22 μm filtered solution in 50 mM Tris-HCl, 1 mM DTT, 150 mM NaCl. (pH 8.0). Contact us for customized product form or formulation.
描述
Recombinant Human WEE1 Kinase is produced by Baculovirus-Insect Cells expression system. The target protein is expressed with sequence (Met291-Lys575) of Human WEE1 (Accession #P30291) fused with No tag.
储存
Store at -70°C. This product is stable at ≤ -70°C for up to 1 year from the date of receipt. For optimal storage, aliquot into smaller quantities after centrifugation and store at recommended temperature.
Aliquots below 10 μL are not advisable. Product must not be stored in diluted solutions. Avoid repeated freeze-thaw cycles.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月；
复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周。
生物活性
The activity of Wee1 is based on the ADP-GLO kinase activity assay quantifies kinase activity by measuring the conversion of ATP to ADP catalyzed by the kinase. Specific reagents are used to convert the ADP in the reaction back to ATP, resulting in the production of a luminescent signal.
复溶
Please use running water to thaw it quickly.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。
请在蛋白复溶计算器中输入蛋白总质量和所需终浓度，快速计算您需要添加溶液的体积吧！
Wee1 is a nuclear kinase belonging to the Ser/Thr family of protein kinases in the fission yeast Schizosaccharomyces pombe (S. pombe). Wee1 has a molecular mass of 96 kDa and is a key regulator of cell cycle progression. Wee1 inhibits Cdk1 by phosphorylating it on two different sites, Tyr15 and Thr14. Cdk1 is crucial for the cyclin-dependent passage of the various cell cycle checkpoints. To date, there have not been many Wee1 inhibitors developed and at the clinical stage. Adavosertib (AZD1775, MK1755), developed by AstraZeneca, is a small molecule Wee1 inhibitor, and was the first of its kind to reach clinical trials.
